Anne Chain

410 total citations
25 papers, 316 citations indexed

About

Anne Chain is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Anne Chain has authored 25 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 7 papers in Molecular Biology and 6 papers in Infectious Diseases. Recurrent topics in Anne Chain's work include Cardiac electrophysiology and arrhythmias (8 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Nausea and vomiting management (3 papers). Anne Chain is often cited by papers focused on Cardiac electrophysiology and arrhythmias (8 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Nausea and vomiting management (3 papers). Anne Chain collaborates with scholars based in United States, Netherlands and United Kingdom. Anne Chain's co-authors include Oscar Della Pasqua, Meindert Danhof, Miriam Sturkenboom, Lokesh Jain, Dinesh de Alwis, Anna Kondic, Ruth Perets, Mallika Lala, Byoung Chul Cho and Myung‐Ju Ahn and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and British Journal of Pharmacology.

In The Last Decade

Anne Chain

24 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Chain United States	11	108	92	67	46	44	25	316
Marie‐Blanche Valnet‐Rabier France	13	83 0.8×	97 1.1×	37 0.6×	43 0.9×	29 0.7×	28	478
Joanna Drozd‐Sokołowska Poland	11	79 0.7×	52 0.6×	97 1.4×	30 0.7×	35 0.8×	74	389
Ashit Trivedi United States	9	64 0.6×	114 1.2×	53 0.8×	35 0.8×	26 0.6×	29	316
Mindy Magee United States	14	51 0.5×	124 1.3×	59 0.9×	43 0.9×	77 1.8×	41	567
Lucette Doessegger Switzerland	8	44 0.4×	108 1.2×	62 0.9×	55 1.2×	26 0.6×	12	340
Selina Moy United States	9	49 0.5×	55 0.6×	55 0.8×	14 0.3×	24 0.5×	16	383
Loretta Fala United States	14	47 0.4×	117 1.3×	58 0.9×	56 1.2×	61 1.4×	24	392
A. D. R. Huitema Netherlands	13	131 1.2×	95 1.0×	19 0.3×	18 0.4×	59 1.3×	26	432
Jacqueline L. Olin United States	13	92 0.9×	117 1.3×	26 0.4×	10 0.2×	57 1.3×	36	468
Danielle Armas United States	9	52 0.5×	74 0.8×	65 1.0×	9 0.2×	74 1.7×	18	312

Countries citing papers authored by Anne Chain

Since Specialization

Citations

This map shows the geographic impact of Anne Chain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Chain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Chain more than expected).

Fields of papers citing papers by Anne Chain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Chain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Chain. The network helps show where Anne Chain may publish in the future.

Co-authorship network of co-authors of Anne Chain

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Chain. A scholar is included among the top collaborators of Anne Chain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Chain. Anne Chain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sheng, Xinan, Hongqian Guo, Xin Yao, et al.. (2024). Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.. Journal of Clinical Oncology. 42(16_suppl). 4537–4537. 1 indexed citations

Marathe, Dhananjay, Huub Jan Kleijn, Anne Chain, et al.. (2024). Exposure–Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling. The Journal of Clinical Pharmacology. 64(10). 1246–1258. 2 indexed citations

Marathe, Dhananjay, Huub Jan Kleijn, Anne Chain, et al.. (2023). Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1499–1510. 11 indexed citations

Clarke, Diana F., Edward P. Acosta, Jiajia Wang, et al.. (2020). Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(5). 626–634. 1 indexed citations

Morissette, Pierre, Sebastian Polak, Anne Chain, et al.. (2020). Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay. Toxicology and Applied Pharmacology. 390. 114883–114883. 5 indexed citations

Perets, Ruth, Jair Bar, Drew Rasco, et al.. (2020). Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Annals of Oncology. 32(3). 395–403. 65 indexed citations

Clarke, Diana F., Edward P. Acosta, Jiajia Wang, et al.. (2020). Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1–Exposed Neonates at Risk of Infection (IMPAACT P1110). JAIDS Journal of Acquired Immune Deficiency Syndromes. 84(1). 70–77. 13 indexed citations

Clarke, Diana F., Mark Mirochnick, Edward P. Acosta, et al.. (2019). Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. JAIDS Journal of Acquired Immune Deficiency Syndromes. 82(4). 392–398. 5 indexed citations

Jain, Lokesh, Anne Chain, Daniel Tatosian, et al.. (2019). Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin. British Journal of Clinical Pharmacology. 85(12). 2759–2771. 7 indexed citations

10.

Stone, Julie A., Ellen Snyder, Leslie Lipka, et al.. (2019). Immunogenicity of pembrolizumab in patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 7(1). 212–212. 44 indexed citations

11.

Mora, Jaume, et al.. (2019). Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients. Pediatric Blood & Cancer. 66(6). 11 indexed citations

12.

Dockendorf, Marissa F., et al.. (2018). Leveraging model-informed approaches for drug discovery and development in the cardiovascular space. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 355–364. 4 indexed citations

13.

Chain, Anne, et al.. (2018). Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. Journal of Pediatric Surgery. 54(7). 1384–1390. 11 indexed citations

14.

Nayak, Satyaprakash, Oliver Sander, Nidal Al‐Huniti, et al.. (2018). Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use. Clinical Pharmacology & Therapeutics. 103(3). 378–383. 20 indexed citations

15.

Gurkan, Sevgi, Fang Liu, Anne Chain, & David E. Gutstein. (2018). A Study to Assess the Proarrhythmic Potential of Mirtazapine Using Concentration‐QTc (C‐QTc) Analysis. Clinical Pharmacology in Drug Development. 8(4). 449–458. 5 indexed citations

16.

Gheyas, Ferdous, Junghoon Lee, Anne Chain, et al.. (2015). Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar. Journal of Pharmacokinetics and Pharmacodynamics. 42. 1 indexed citations

17.

Chain, Anne, et al.. (2013). Identifying the translational gap in the evaluation of drug‐induced QT_c interval prolongation. British Journal of Clinical Pharmacology. 76(5). 708–724. 31 indexed citations

18.

Chain, Anne, Miriam Sturkenboom, Meindert Danhof, & Oscar Della Pasqua. (2012). Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology. Drug Discovery Today Technologies. 10(3). e373–e383. 4 indexed citations

19.

Chain, Anne, et al.. (2011). Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Clinical Drug Development. Clinical Pharmacology & Therapeutics. 90(6). 867–875. 22 indexed citations

20.

Huntjens, Dymphy, Anne Chain, Scott Summerfield, et al.. (2008). Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. British Journal of Pharmacology. 153(5). 1072–1084. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact